Zealand Pharma sets up CSAB
This article was originally published in Scrip
Zealand Pharma, a Danish biopharmaceutical company discovering and developing innovative peptide drugs has appointed a new clinical and scientific advisory board. Dr Alain Munoz, a Zealand board member and Dr Christian Groendahl, Zealand's CSO, will jointly chair the CSAB. Other members include: Dr Bernard Charbonnel, professor of endocrinology and metabolic diseases at the University of Nantes; Dr Richard Pratley, medical director of the Florida Hospital Diabetes Institute; Dr Paul Dorian, department director for the University of Toronto's division of cardiology and staff electrophysiologist at St Michael's Hospital; Dr Ake Lernmark, professor of experimental diabetes at Lund University in Malmo, Seden and professor emeritus of medicine at the University of Washington; and Dr Gert Van Assche, professor of medicine at the University of Leuven, Belgium.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.